Mitochondrial Bioenergetics and Role in Cellular Damage in Ischemic Myocardium

• Conditions: Coronary Artery Disease; Diabetes Mellitus; Mitochondrial Metabolism Disorders

• Registration Number: NCT03179137
• Lead Sponsor: University of Split, School of Medicine

Brief Summary

Cardiac ischemia is a common pathological condition, known to elicit multiple pathological processes at the cellular level. One of the most affected is thought to be cellular metabolism, key for the adequate cardiac function. The aim is to study mitochondrial bioenergetic function, interaction with other cellular systems and influence of several co-morbidities in myocardium of the affected patients.

Detailed Description

Coronary artery disease, one of the most common pathologies in the developed world, causes hypoperfusion of myocardial tissue, usually evident by the presence of anginal pain. This myocardial ischemia elicits alterations in normal cardiomyocyte physiology, which gradually deteriorate cellular function, affecting the performance of the entire organ. The condition is frequently further complicated (and aggravated) by the presence of various co-morbidities, such as diabetes mellitus. The primary aim of this study is to investigate the cardiomyocyte bioenergetics and the consequences of potentially reduced mitochondrial metabolic function in ischemic heart, and evaluate the potential contribution of other conditions, primarily ones affecting metabolic homeostasis.

Study Timeline

• Study Start: 2016-10-01
• Study First Submitted: 2017-05-30
• Study First Submitted QC: 2017-06-05
• Study First Posted: 2017-06-07
• Status Verified: 2020-06
• Last Update Submitted: 2020-06-17
• Last Update Posted: 2020-06-19
• Primary Completion: 2021-04-01
• Study Completion: 2021-10-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Coronary artery disease
• Indication for coronary artery bypass grafting surgery

Exclusion Criteria

• Emergency patients
• Patients with LV ejection fraction (LVEF) below 30%
• Patients with severe renal, hepatic or pulmonary disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mitochondrial oxygen consumption (rate of oxygen consumption per milligram of left ventricular tissue)	2016-2020	Mitochondrial respiration in nmol O2/minute/mg of tissue weight will be measured as an indicator of mitochondrial ATP production capacity, using different metabolic substrates
Myocardial production of reactive oxygen species	2016-2020	Myocardial production of reactive oxygen species will be measured using electron paramagnetic resonance and fluorometry

Secondary Outcome Measures

Name	Time	Method
Anti-cardiolipin antibodies in the blood of patients with symptoms of cardiac ischemia	2016-2020	Anticardiolipin antibodies assessed in venous blood of patients with angina pectoris undergoing coronary angiography

Trial Locations

Locations (1)

School of Medicine, University of Split; 🇭🇷 Split, Croatia